Applied Genetic Technologies Corporation (AGTC) Receives Analyst Rating

Applied Genetic Technologies Corporation (AGTC) has an average broker rating of 2.43, which is interpreted as a Buy, as rated by 7 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Applied Genetic Technologies Corporation (AGTC) stock is expected to deviate a maximum of $8.09 from the average target price of $20.67 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $32 and the most muted being $11.


Applied Genetic Technologies Corporation (NASDAQ:AGTC): The stock opened in the green at $8.68 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $8.93 and a low of $8.59 for the day. The stock did not find buyers even at the lows and closed at $8.62 recording a loss of -2.49%. 557,796 shares exchanged hands during the trading day. The stock had closed at $8.84 in the previous days trading.

Applied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis, an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia, an inherited condition that is associated with color blindness, visual acuity loss, and extreme light sensitivity resulting in daytime blindness.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.